Panitumumab submitted in competitive Japan market
This article was originally published in Scrip
Executive Summary
Takedahas filed for the Japanese approval of panitumumab, although the EGFR-targeting monoclonal antibody will face stiff competition in its lead target indication of metastatic colorectal cancer should it be approved and reach the market.